-
![Pyrazolo[3,4-d]pyrimidine compounds](/abs-image/US/2011/06/21/US07964607B2/abs.jpg.150x150.jpg)
公开(公告)号：US07964607B2
公开(公告)日：2011-06-21
申请号：US12118062
申请日：2008-05-09
IPC分类号： C07D487/04 , A61K31/519 , A61P25/28
CPC分类号： C07D487/04
摘要： The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R1, R2 and R3 are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.
摘要翻译： 本发明提供抑制PDE9的式（I）化合物及其药学上可接受的盐，其中R，R 1，R 2和R 3如本文所定义。 还提供了含有式I化合物的药物组合物及其用于治疗神经变性和认知障碍如阿尔茨海默病和精神分裂症的用途。
-
2.发明申请SUCCINATE SALT OF 2-((4-(1-METHYL-4-PYRIDIN-4-YL)-1H-PYRAZOL-3-YL)PHENOXY)METHYL)QUINOLINE 有权2 - （（4-（1-甲基-4-吡啶-4-基）-1H-吡唑-3-基）苯基）甲基）喹啉的磺酸盐公开(公告)号：US20100063089A1
公开(公告)日：2010-03-11
申请号：US12515612
申请日：2007-12-03
IPC分类号： A61K31/4709 , C07D401/14 , A61P25/00 , A61P25/18 , A61P25/30 , A61P25/28 , A61P25/16 , A61P25/24
CPC分类号： C07D401/14
摘要： The present invention relates to a succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline, and to a method for treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal the succinate salt. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and the succinate salt.
摘要翻译： 本发明涉及2 - （（4-（1-甲基-4-（吡啶-4-基）-1H-吡唑-3-基）苯氧基）甲基）喹啉的琥珀酸盐， 通过向哺乳动物施用琥珀酸盐，中枢神经系统（CNS）的紊乱和哺乳动物（包括人）中的其它疾病。 它还涉及含有药学上可接受的载体和琥珀酸盐的药物组合物。
-
3.发明授权Succinate salt of 2-((4-(1-methyl-4-pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline 有权2 - （（4-（1-甲基-4-吡啶-4-基）-1H-吡唑-3-基）苯氧基）甲基）喹啉的琥珀酸盐公开(公告)号：US08283471B2
公开(公告)日：2012-10-09
申请号：US12515612
申请日：2007-12-03
IPC分类号： C07D215/12 , A61K31/4709
CPC分类号： C07D401/14
摘要： The present invention relates to a succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline, and to a method for treating disorders of the Central Nervous System (CNS) and other disorders in a mammal, including a human, by administering to the mammal the succinate salt. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier and the succinate salt.
摘要翻译： 本发明涉及2 - （（4-（1-甲基-4-（吡啶-4-基）-1H-吡唑-3-基）苯氧基）甲基）喹啉的琥珀酸盐， 通过向哺乳动物施用琥珀酸盐，中枢神经系统（CNS）的紊乱和哺乳动物（包括人）中的其它疾病。 它还涉及含有药学上可接受的载体和琥珀酸盐的药物组合物。
-
公开(公告)号：US20090030003A1
公开(公告)日：2009-01-29
申请号：US12118062
申请日：2008-05-09
IPC分类号： A61K31/519 , C07D487/04 , A61P25/28
CPC分类号： C07D487/04
摘要： The invention provides PDE9-inhibiting compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R, R1, R2 and R3 are as defined herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in treating neurodegenerative and cognitive disorders, such as Alzheimer's disease and schizophrenia, are also provided.
摘要翻译： 本发明提供抑制PDE9的式（I）化合物及其药学上可接受的盐，其中R，R 1，R 2和R 3如本文所定义。 还提供了含有式I化合物的药物组合物及其用于治疗神经变性和认知障碍如阿尔茨海默病和精神分裂症的用途。
-
-
-
搜索结果
4 条记录 (耗时 0.032 秒)
